PMID- 34473343 OWN - NLM STAT- MEDLINE DCOM- 20211124 LR - 20230216 IS - 1469-493X (Electronic) IS - 1361-6137 (Linking) VI - 9 IP - 9 DP - 2021 Sep 2 TI - SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. PG - CD013825 LID - 10.1002/14651858.CD013825.pub2 [doi] LID - CD013825 AB - BACKGROUND: Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID-19). OBJECTIVES: To assess the effectiveness and safety of SARS-CoV-2-neutralising mAbs for treating patients with COVID-19, compared to an active comparator, placebo, or no intervention. To maintain the currency of the evidence, we will use a living systematic review approach. A secondary objective is to track newly developed SARS-CoV-2-targeting mAbs from first tests in humans onwards. SEARCH METHODS: We searched MEDLINE, Embase, the Cochrane COVID-19 Study Register, and three other databases on 17 June 2021. We also checked references, searched citations, and contacted study authors to identify additional studies. Between submission and publication, we conducted a shortened randomised controlled trial (RCT)-only search on 30 July 2021. SELECTION CRITERIA: We included studies that evaluated SARS-CoV-2-neutralising mAbs, alone or combined, compared to an active comparator, placebo, or no intervention, to treat people with COVID-19. We excluded studies on prophylactic use of SARS-CoV-2-neutralising mAbs. DATA COLLECTION AND ANALYSIS: Two authors independently assessed search results, extracted data, and assessed risk of bias using the Cochrane risk of bias tool (RoB2). Prioritised outcomes were all-cause mortality by days 30 and 60, clinical progression, quality of life, admission to hospital, adverse events (AEs), and serious adverse events (SAEs). We rated the certainty of evidence using GRADE. MAIN RESULTS: We identified six RCTs that provided results from 17,495 participants with planned completion dates between July 2021 and December 2031. Target sample sizes varied from 1020 to 10,000 participants. Average age was 42 to 53 years across four studies of non-hospitalised participants, and 61 years in two studies of hospitalised participants. Non-hospitalised individuals with COVID-19 Four studies evaluated single agents bamlanivimab (N = 465), sotrovimab (N = 868), regdanvimab (N = 307), and combinations of bamlanivimab/etesevimab (N = 1035), and casirivimab/imdevimab (N = 799). We did not identify data for mortality at 60 days or quality of life. Our certainty of the evidence is low for all outcomes due to too few events (very serious imprecision). Bamlanivimab compared to placebo No deaths occurred in the study by day 29. There were nine people admitted to hospital by day 29 out of 156 in the placebo group compared with one out of 101 in the group treated with 0.7 g bamlanivimab (risk ratio (RR) 0.17, 95% confidence interval (CI) 0.02 to 1.33), 2 from 107 in the group treated with 2.8 g (RR 0.32, 95% CI 0.07 to 1.47) and 2 from 101 in the group treated with 7.0 g (RR 0.34, 95% CI 0.08 to 1.56). Treatment with 0.7 g, 2.8 g and 7.0 g bamlanivimab may have similar rates of AEs as placebo (RR 0.99, 95% CI 0.66 to 1.50; RR 0.90, 95% CI 0.59 to 1.38; RR 0.81, 95% CI 0.52 to 1.27). The effect on SAEs is uncertain. Clinical progression/improvement of symptoms or development of severe symptoms were not reported. Bamlanivimab/etesevimab compared to placebo There were 10 deaths in the placebo group and none in bamlanivimab/etesevimab group by day 30 (RR 0.05, 95% CI 0.00 to 0.81). Bamlanivimab/etesevimab may decrease hospital admission by day 29 (RR 0.30, 95% CI 0.16 to 0.59), may result in a slight increase in any grade AEs (RR 1.15, 95% CI 0.83 to 1.59) and may increase SAEs (RR 1.40, 95% CI 0.45 to 4.37). Clinical progression/improvement of symptoms or development of severe symptoms were not reported. Casirivimab/imdevimab compared to placebo Casirivimab/imdevimab may reduce hospital admissions or death (2.4 g: RR 0.43, 95% CI 0.08 to 2.19; 8.0 g: RR 0.21, 95% CI 0.02 to 1.79). We are uncertain of the effect on grades 3-4 AEs (2.4 g: RR 0.76, 95% CI 0.17 to 3.37; 8.0 g: RR 0.50, 95% CI 0.09 to 2.73) and SAEs (2.4 g: RR 0.68, 95% CI 0.19 to 2.37; 8.0 g: RR 0.34, 95% CI 0.07 to 1.65). Mortality by day 30 and clinical progression/improvement of symptoms or development of severe symptoms were not reported. Sotrovimab compared to placebo We are uncertain whether sotrovimab has an effect on mortality (RR 0.33, 95% CI 0.01 to 8.18) and invasive mechanical ventilation (IMV) requirement or death (RR 0.14, 95% CI 0.01 to 2.76). Treatment with sotrovimab may reduce the number of participants with oxygen requirement (RR 0.11, 95 % CI 0.02 to 0.45), hospital admission or death by day 30 (RR 0.14, 95% CI 0.04 to 0.48), grades 3-4 AEs (RR 0.26, 95% CI 0.12 to 0.60), SAEs (RR 0.27, 95% CI 0.12 to 0.63) and may have little or no effect on any grade AEs (RR 0.87, 95% CI 0.66 to 1.16). Regdanvimab compared to placebo Treatment with either dose (40 or 80 mg/kg) compared with placebo may decrease hospital admissions or death (RR 0.45, 95% CI 0.14 to 1.42; RR 0.56, 95% CI 0.19 to 1.60, 206 participants), but may increase grades 3-4 AEs (RR 2.62, 95% CI 0.52 to 13.12; RR 2.00, 95% CI 0.37 to 10.70). 80 mg/kg may reduce any grade AEs (RR 0.79, 95% CI 0.52 to 1.22) but 40 mg/kg may have little to no effect (RR 0.96, 95% CI 0.64 to 1.43). There were too few events to allow meaningful judgment for the outcomes mortality by 30 days, IMV requirement, and SAEs. Hospitalised individuals with COVID-19 Two studies evaluating bamlanivimab as a single agent (N = 314) and casirivimab/imdevimab as a combination therapy (N = 9785) were included. Bamlanivimab compared to placebo We are uncertain whether bamlanivimab has an effect on mortality by day 30 (RR 1.39, 95% CI 0.40 to 4.83) and SAEs by day 28 (RR 0.93, 95% CI 0.27 to 3.14). Bamlanivimab may have little to no effect on time to hospital discharge (HR 0.97, 95% CI 0.78 to 1.20) and mortality by day 90 (HR 1.09, 95% CI 0.49 to 2.43). The effect of bamlanivimab on the development of severe symptoms at day 5 (RR 1.17, 95% CI 0.75 to 1.85) is uncertain. Bamlanivimab may increase grades 3-4 AEs at day 28 (RR 1.27, 95% CI 0.81 to 1.98). We assessed the evidence as low certainty for all outcomes due to serious imprecision, and very low certainty for severe symptoms because of additional concerns about indirectness. Casirivimab/imdevimab with usual care compared to usual care alone Treatment with casirivimab/imdevimab compared to usual care probably has little or no effect on mortality by day 30 (RR 0.94, 95% CI 0.87 to 1.02), IMV requirement or death (RR 0.96, 95% CI 0.90 to 1.04), nor alive at hospital discharge by day 30 (RR 1.01, 95% CI 0.98 to 1.04). We assessed the evidence as moderate certainty due to study limitations (lack of blinding). AEs and SAEs were not reported. AUTHORS' CONCLUSIONS: The evidence for each comparison is based on single studies. None of these measured quality of life. Our certainty in the evidence for all non-hospitalised individuals is low, and for hospitalised individuals is very low to moderate. We consider the current evidence insufficient to draw meaningful conclusions regarding treatment with SARS-CoV-2-neutralising mAbs. Further studies and long-term data from the existing studies are needed to confirm or refute these initial findings, and to understand how the emergence of SARS-CoV-2 variants may impact the effectiveness of SARS-CoV-2-neutralising mAbs. Publication of the 36 ongoing studies may resolve uncertainties about the effectiveness and safety of SARS-CoV-2-neutralising mAbs for the treatment of COVID-19 and possible subgroup differences. CI - Copyright (c) 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. FAU - Kreuzberger, Nina AU - Kreuzberger N AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Hirsch, Caroline AU - Hirsch C AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Chai, Khai Li AU - Chai KL AD - Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. FAU - Tomlinson, Eve AU - Tomlinson E AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. FAU - Khosravi, Zahra AU - Khosravi Z AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Popp, Maria AU - Popp M AD - Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Wuerzburg, Wuerzburg, Germany. FAU - Neidhardt, Miriam AU - Neidhardt M AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Piechotta, Vanessa AU - Piechotta V AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Salomon, Susanne AU - Salomon S AD - Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Valk, Sarah J AU - Valk SJ AD - Jon J van Rood Center for Clinical Transfusion Research, Sanquin/Leiden University Medical Center, Leiden, Netherlands. FAU - Monsef, Ina AU - Monsef I AD - Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. FAU - Schmaderer, Christoph AU - Schmaderer C AD - Department of Nephrology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany. FAU - Wood, Erica M AU - Wood EM AD - Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. FAU - So-Osman, Cynthia AU - So-Osman C AD - Erasmus Medical Centre, Rotterdam, Netherlands. FAU - Roberts, David J AU - Roberts DJ AD - Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK. FAU - McQuilten, Zoe AU - McQuilten Z AD - Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. FAU - Estcourt, Lise J AU - Estcourt LJ AD - Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK. FAU - Skoetz, Nicole AU - Skoetz N AD - Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. LA - eng SI - ClinicalTrials.gov/NCT04501978 SI - ClinicalTrials.gov/NCT04427501 SI - ClinicalTrials.gov/NCT04545060 SI - ClinicalTrials.gov/NCT04602000 SI - ClinicalTrials.gov/NCT04381936 SI - ClinicalTrials.gov/NCT04425629 SI - ClinicalTrials.gov/NCT04505774 SI - ClinicalTrials.gov/NCT04280705 SI - ClinicalTrials.gov/NCT04401579 SI - ClinicalTrials.gov/NCT04492475 SI - ClinicalTrials.gov/NCT04602260 SI - ClinicalTrials.gov/NCT04356495 SI - ClinicalTrials.gov/NCT04561063 SI - ClinicalTrials.gov/NCT04333732 SI - ClinicalTrials.gov/NCT04534725 SI - ClinicalTrials.gov/NCT04371367 SI - ClinicalTrials.gov/NCT04382651 SI - ClinicalTrials.gov/NCT04275245 SI - ClinicalTrials.gov/NCT04341116 SI - ClinicalTrials.gov/NCT04354428 SI - ClinicalTrials.gov/NCT04369469 SI - ClinicalTrials.gov/NCT04370262 SI - ClinicalTrials.gov/NCT04415073 SI - ClinicalTrials.gov/NCT04453384 SI - ClinicalTrials.gov/NCT04454398 SI - ClinicalTrials.gov/NCT04469179 SI - ClinicalTrials.gov/NCT04494724 SI - ClinicalTrials.gov/NCT04494984 SI - ClinicalTrials.gov/NCT04497987 SI - ClinicalTrials.gov/NCT04498273 SI - ClinicalTrials.gov/NCT04516564 SI - ClinicalTrials.gov/NCT04569786 SI - ClinicalTrials.gov/NCT04574869 SI - ClinicalTrials.gov/NCT04586153 SI - ClinicalTrials.gov/NCT04629703 SI - ClinicalTrials.gov/NCT04766671 SI - ClinicalTrials.gov/NCT04859517 SI - ClinicalTrials.gov/NCT04894474 SI - ClinicalTrials.gov/NCT04333420 SI - ClinicalTrials.gov/NCT04621149 SI - ClinicalTrials.gov/NCT04625972 SI - ClinicalTrials.gov/NCT04429529 SI - ClinicalTrials.gov/NCT04441918 SI - ClinicalTrials.gov/NCT04441931 SI - ClinicalTrials.gov/NCT04479631 SI - ClinicalTrials.gov/NCT04479644 SI - ClinicalTrials.gov/NCT04483375 SI - ClinicalTrials.gov/NCT04507256 SI - ClinicalTrials.gov/NCT04519437 SI - ClinicalTrials.gov/NCT04525079 SI - ClinicalTrials.gov/NCT04532294 SI - ClinicalTrials.gov/NCT04533048 SI - ClinicalTrials.gov/NCT04537910 SI - ClinicalTrials.gov/NCT04561076 SI - ClinicalTrials.gov/NCT04567810 SI - ClinicalTrials.gov/NCT04590430 SI - ClinicalTrials.gov/NCT04592549 SI - ClinicalTrials.gov/NCT04603651 SI - ClinicalTrials.gov/NCT04617535 SI - ClinicalTrials.gov/NCT04656691 SI - ClinicalTrials.gov/NCT04691180 SI - ClinicalTrials.gov/NCT04700163 SI - ClinicalTrials.gov/NCT04701658 SI - ClinicalTrials.gov/NCT04896541 SI - ClinicalTrials.gov/NCT04932850 SI - ClinicalTrials.gov/NCT04351724 SI - ClinicalTrials.gov/NCT04593940 SI - ClinicalTrials.gov/NCT04640168 SI - ClinicalTrials.gov/NCT04583956 SI - ClinicalTrials.gov/NCT04583969 SI - ClinicalTrials.gov/NCT04355143 SI - ClinicalTrials.gov/NCT04662086 SI - ClinicalTrials.gov/NCT04324047 SI - ClinicalTrials.gov/NCT04328012 SI - ClinicalTrials.gov/NCT04473053 SI - ClinicalTrials.gov/NCT04891133 SI - ClinicalTrials.gov/NCT04488081 SI - ClinicalTrials.gov/NCT04590586 SI - ClinicalTrials.gov/NCT04452318 SI - ClinicalTrials.gov/NCT04703608 SI - ClinicalTrials.gov/NCT04386070 SI - ClinicalTrials.gov/NCT02735707 SI - ClinicalTrials.gov/NCT04826588 SI - ClinicalTrials.gov/NCT04393246 SI - ClinicalTrials.gov/NCT04390464 SI - ClinicalTrials.gov/NCT04445467 SI - ClinicalTrials.gov/NCT04518410 SI - ClinicalTrials.gov/NCT04746183 SI - ClinicalTrials.gov/NCT04315948 SI - ClinicalTrials.gov/NCT04411628 SI - ClinicalTrials.gov/NCT04426695 SI - ClinicalTrials.gov/NCT04551898 SI - ClinicalTrials.gov/NCT04584697 SI - ClinicalTrials.gov/NCT04593641 SI - ClinicalTrials.gov/NCT04627584 SI - ClinicalTrials.gov/NCT04631666 SI - ClinicalTrials.gov/NCT04631705 SI - ClinicalTrials.gov/NCT04634409 SI - ClinicalTrials.gov/NCT04644120 SI - ClinicalTrials.gov/NCT04644185 SI - ClinicalTrials.gov/NCT04649515 SI - ClinicalTrials.gov/NCT04666441 SI - ClinicalTrials.gov/NCT04674566 SI - ClinicalTrials.gov/NCT04683328 SI - ClinicalTrials.gov/NCT04709328 SI - ClinicalTrials.gov/NCT04723394 SI - ClinicalTrials.gov/NCT04734860 SI - ClinicalTrials.gov/NCT04748588 SI - ClinicalTrials.gov/NCT04770467 SI - ClinicalTrials.gov/NCT04771351 SI - ClinicalTrials.gov/NCT04779879 SI - ClinicalTrials.gov/NCT04780321 SI - ClinicalTrials.gov/NCT04787211 SI - ClinicalTrials.gov/NCT04796402 SI - ClinicalTrials.gov/NCT04805671 SI - ClinicalTrials.gov/NCT04822701 SI - ClinicalTrials.gov/NCT04900428 SI - ClinicalTrials.gov/NCT04913675 SI - ClinicalTrials.gov/NCT04952805 SI - ClinicalTrials.gov/NCT04790786 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PT - Systematic Review DEP - 20210902 PL - England TA - Cochrane Database Syst Rev JT - The Cochrane database of systematic reviews JID - 100909747 RN - 0 (Antibodies, Monoclonal) SB - IM UOF - doi: 10.1002/14651858.CD013825 MH - Adult MH - Antibodies, Monoclonal/therapeutic use MH - *COVID-19 MH - Cause of Death MH - Humans MH - Middle Aged MH - Randomized Controlled Trials as Topic MH - *SARS-CoV-2 PMC - PMC8411904 COIS- NK: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project 'COVIM', which was paid to the institution). CH: none known KLC: none known ET: none known ZK: none known MP: none known MN: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project 'COVIM', which was paid to the institution). VP: none known SS: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project 'COVIM' which was paid to the institution). SJV: receives a PhD scholarship from the not-for-profit Sanquin blood bank. IM: none known CS: none known EMW: none known CS-O: has declared to be employed by the not-for-profit Sanquin blood bank. DJR: is a consultant haematologist for NHS Blood and Transplant. ZM: is a haematologist at Monash University. LJE: is a consultant haematologist for NHS Blood and Transplant. NS: none known EDAT- 2021/09/03 06:00 MHDA- 2021/11/25 06:00 PMCR- 2022/09/02 CRDT- 2021/09/02 12:26 PHST- 2021/09/02 12:26 [entrez] PHST- 2021/09/03 06:00 [pubmed] PHST- 2021/11/25 06:00 [medline] PHST- 2022/09/02 00:00 [pmc-release] AID - CD013825.pub2 [pii] AID - 10.1002/14651858.CD013825.pub2 [doi] PST - epublish SO - Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.